Viking Therapeutics (STU:1VT) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1VT Viking Therapeutics Inc STU:1VT
38 GF Score
Price €29.00
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:1VT
38GF Score
Viking Therapeutics Inc STU:1VT
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics Business Description

Other Exchanges VKTX:USA1VKTX:Italy0VQA:UK
Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
38GF Score

Get the complete analysis for STU:1VT

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.00
Price